FDA Press AnnouncementsUnited States17 September 2026
FDA Approves First Gene Therapy for Pediatric Patients with Sanfilippo Syndrome Type A
This is an official announcement record
Firsthand records what FDA Press Announcements announced and links to the original. The wording below is theirs, not ours.
The U.S. Food and Drug Administration today approved Fayuvi (rebisufligene etisparvovec-hopf), the first treatment for pediatric patients with mucopolysaccharidosis type IIIA (MPS IIIA), also known as Sanfilippo syndrome type A.
Read the official announcement
Opens www.fda.gov
More from FDA Press Announcements
- FDA Approves First Heart Valve Designed to Grow with Children1 October 2026
- FDA Launches Nationwide Effort to Expand Scientific Expertise and Consumer Voices to Advisory Committees30 September 2026
- FDA Investigation Leads to Charges Against Two Indian Nationals Involved in Transnational Counterfeit Drug Distribution Scheme29 September 2026
- FDA Approves First Treatment for MCT8 Deficiency28 September 2026
- FDA intends to evaluate changes to the PMTA regulatory framework28 September 2026
This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program — especially if you are pregnant, nursing, taking medication, or managing a health condition.